[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"mycobacterium-avium\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:mycobacterium-avium":24},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,1,0,[8],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":22,"conditions":23,"keywords":29,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":34,"lastUpdatePostDateStruct":35,"startDateStruct":38,"completionDateStruct":40,"leadSponsor":42,"locationsCount":5},"100536562","m-avium-wgs-during-mav-pd-treatment-100536562",false,"NCT06266442","M. Avium WGS During Mav-PD Treatment","Longitudinal Assessment of Clinical Pulmonary Mycobacterium Avium Isolates in Treated Patients Using Whole Genome Sequencing","Inclusion Criteria:\n\n* Age 18 and older\n* Willing to provide informed consent and participate in study procedures\n* Residing continuously in Ontario during the past five years\n* Mav-PD, either initial or recurrent (previously treated patients will be eligible) five years\n* Meet American Thoracic Society (ATS) \u002F Infectious Diseases Society of America (IDSA) NTM disease criteria for Mav-PD\n\nExclusion Criteria:\n\n* Lack of an available pre-treatment M. avium isolate in the PHOL isolate bank\n* The inability to produce sputum either spontaneously or by induction with nebulized hypertonic saline\n* Cavitation \\>3 cm internal diameter\n* Known macrolide-resistant MAC infection\n* HIV infection\n* Known diagnosis of cystic fibrosis\n* History of solid organ or hematological transplantation\n* Severe comorbid illness that is reasonably expected to limit survival to \\\u003C24 months\n* Residing in mid\u002Fnorth York region (King, Aurora, Newmarket, Whitechurch-Stouffville, East Gwillimbury or Georgina)\n* Having moved between regions (Toronto\u002Fsouthern York region vs non-Toronto\u002FYork region vs mid-northern York region) within the past 5 years","ALL","18 Years",{"count":19,"type":20},40,"ESTIMATED","OBSERVATIONAL","This is a prospective observational study using whole genome sequencing (WGS) to investigate whether new strains (other than the initially identified strain(s)) of M. avium are responsible for persistently culture positive sputum during treatment (refractory disease), or the reversion to culture positive sputum after prior conversion to negative. The study will further investigate for differences between participants living in the Toronto\u002FYork region versus participants living elsewhere.\n\nThe primary goal of this prospective observational study is to understand why some patients with M. avium lung disease have persistent or recurrent M. avium in their sputum despite treatment. The aim is to understand whether it is usually due to treatment failure or new infection.",[24,25,26,27,28],"Mycobacterium Avium","Mycobacterium Infections, Nontuberculous","Mycobacterium Infections","Nontuberculous Mycobacterial Lung Disease","Respiratory Tract Diseases",[30,31,32],"Nontuberculous mycobacterium","Whole genome sequencing","Mycobacterium avium","RECRUITING","2024-05-17",{"date":36,"type":37},"2024-05-21","ACTUAL",{"date":39,"type":37},"2024-05-13",{"date":41,"type":20},"2026-09",{"name":43,"class":44},"University Health Network, Toronto","OTHER"]